Daihan Scientific

대한과학 · 131220

Industrials Trading & Distribution · KOSDAQ

Small-cap

Market cap US$21.3M (₩29.3B)

Overview

Daihan Scientific supplies laboratory instruments and equipment, the tools researchers use daily in scientific and medical labs, sourcing from hundreds of manufacturers worldwide and distributing tens of thousands of product types through dealer networks at home and abroad.

Its customers include research institutions, universities, and medical facilities in Korea and across roughly seventy countries. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across both distribution and in-house manufacturing, and has expanded into medical-device distribution and value-added services such as calibration, rental, and lab consulting.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$58.8M
▲ +13.1% YoY
Operating profit · FY2025
US$4M
▲ +30.9% YoY
Net income · FY2025
US$3.5M
▲ +21.7% YoY

Revenue

  • FY2023US$53.4M
  • FY2024US$52M
  • FY2025US$58.8M

Operating profit

  • FY2023US$4.5M
  • FY2024US$3.1M
  • FY2025US$4M

Net income

  • FY2023US$3.8M
  • FY2024US$2.8M
  • FY2025US$3.5M

Key ratios (FY2025)

ROE
8.4%
Debt/Eq
27.2%
Op. margin
6.8%
Net margin
5.9%
Rev. YoY
▲ +13.1%

Why it matters

The company has launched a dedicated medical-device distribution arm, Daihan Medical, building out a separate dealer network alongside its core scientific-equipment business.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.